OR2G3

Across TCGA pan-cancer cohorts, OR2G3 Mutation is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated OR2G3 data layer compared with 9 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher OR2G3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR2G3 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ACC, LUAD, and UCEC are the cancer types where OR2G3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.010	0.667	<.001	45	view →
LUAD	OS	Median	III,IV	0.272	0.679	<.001	12	view →
UCEC	OS	Median	IV	0.259	0.770	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	OS	Median	II,III,IV	0.279	0.622	.017	6	view →
BLCA	OS	Median	III,IV	0.187	0.684	.006	6	view →
SKCM	DFS	Median	IV	1.000	0.241	.021	4	view →
HNSC	DFS	Median	II,III,IV	0.208	0.685	.043	3	view →
LIHC	DFS	Median	All	0.096	0.526	.023	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

OR2G3–ACC (DFS)

Open the ACC breakdown →